PMID- 36677015
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230201
IS  - 2218-1989 (Print)
IS  - 2218-1989 (Electronic)
IS  - 2218-1989 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Jan 6
TI  - Simultaneous Quantification of Serum Lipids and Their Association with Type 2 
      Diabetes Mellitus-Positive Hepatocellular Cancer.
LID - 10.3390/metabo13010090 [doi]
LID - 90
AB  - Type 2 diabetes mellitus (T2DM) has been recognized as one of the most important 
      and independent risk factors for hepatocellular cancer (HCC). However, there is 
      still a lack of ideal tumor markers for HCC detection in the T2DM population. 
      Serum lipids have been revealed as potential tumor markers for HCC. In this 
      study, our objective was to develop a novel liquid chromatography-tandem mass 
      spectrometry (LC-MS/MS) method to detect several lipids including 
      8,15-dihydroxy-5,9,11,13-eicosatetraenoic acid (8,15-DiHETE), hexadecanedioic 
      acid (HDA), 15-keto-13,14-dihydroprostaglandin A2 (DHK-PGA2), ricinoleic acid 
      (RCL), octadecanedioic acid (OA) and 16-hydroxy hexadecanoic acid (16OHHA) in 
      serum and explore their diagnostic potential for T2DM-positive [T2DM(+)] HCC. A 
      robust LC-MS/MS method was established for the measurement of 8,15-DiHETE, HDA, 
      DHK-PGA2, RCL, OA, and 16OHHA. The methodology validation was conducted, and the 
      results suggested the reliability of this LC-MS/MS method for targeted lipids. 
      Several serum lipids, including 8,15-DiHETE, HDA, DHK-PGA2, and OA were increased 
      in T2DM(+) HCC patients. A biomarker signature that incorporated HDA, DHK-PGA2, 
      and AFP was established and showed good diagnostic potential for T2DM(+) HCC, and 
      the area under the ROC curve (AUC) was 0.87 for diagnosing T2DM(+) HCC from T2DM 
      individuals. Additionally, the biomarker signature diagnosed small-size (AUC = 
      0.88) and early-stage (AUC = 0.79) tumors with high efficacy. Moreover, the 
      biomarker signature could differentiate T2DM(+) HCC from other T2DM(+) tumors, 
      including pancreatic, gastric and colorectal cancer (AUC = 0.88) as well. In 
      conclusion, our study develops a novel tool for early diagnosis of T2DM(+) HCC in 
      T2DM patients.
FAU - Yue, Zhihong
AU  - Yue Z
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Pei, Lin
AU  - Pei L
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Meng, Guangyan
AU  - Meng G
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Zhang, Aimin
AU  - Zhang A
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Li, Meng
AU  - Li M
AD  - Department of Endocrinology and Metabolism, Peking University People's Hospital, 
      Peking University Diabetes Center, Beijing 100044, China.
FAU - Jia, Mei
AU  - Jia M
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
FAU - Cao, Linlin
AU  - Cao L
AD  - Department of Clinical Laboratory, Peking University People's Hospital, Beijing 
      100044, China.
LA  - eng
GR  - RDJP2022-57/Peking University People's Hospital Scientific Research Development 
      Funds/
PT  - Journal Article
DEP - 20230106
PL  - Switzerland
TA  - Metabolites
JT  - Metabolites
JID - 101578790
PMC - PMC9865394
OTO - NOTNLM
OT  - 15-keto-13,14-dihydroprostaglandin A2
OT  - biomarker signature
OT  - hepatocellular cancer
OT  - hexadecanedioic acid
OT  - serum lipids
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/22 06:01
PMCR- 2023/01/06
CRDT- 2023/01/21 01:39
PHST- 2022/11/20 00:00 [received]
PHST- 2022/12/16 00:00 [revised]
PHST- 2022/12/21 00:00 [accepted]
PHST- 2023/01/21 01:39 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/22 06:01 [medline]
PHST- 2023/01/06 00:00 [pmc-release]
AID - metabo13010090 [pii]
AID - metabolites-13-00090 [pii]
AID - 10.3390/metabo13010090 [doi]
PST - epublish
SO  - Metabolites. 2023 Jan 6;13(1):90. doi: 10.3390/metabo13010090.